Clinical Trial

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Study acronym: SPARKLE-L
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-20; most recent amendment 2026-06-29.
Trial Details
NCT Number NCT06794086
Lead Sponsor Jun Huang
Conditions Colorectal Cancer, Liver Metastases
Enrollment 24 participants
Start Date 2025-04-10
Primary Completion 2026-06-20 (estimated)
Study Completion 2027-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-30